Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine | NEJM - nejm.org

Original Article from The New England Journal of Medicine — Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine

Data from the phase 23 portion of the ongoing pivotal trial of the BNT162b2 vaccine showed that although overall vaccine efficacy was more than 90% for the period from 7 days to 6 months after the se… [+6687 chars]

full article...